The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 7, 2017.
Transcript
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 7.
Number 5: Some health plans are telling consumers that they must purchase brand name drugs, even when cheaper generics are available, leading to higher out-of-pocket costs for patients.
Number 4: The FDA’s Office of Surveillance has released findings from an inspection of Biocon’s troubled manufacturing facility in Bangalore. The investigators found 10 problems, including issues with labeling and sterility.
Number 3: A recent study comparing biosimilar GP2013 to both EU- and US-approved rituximab shows 3-way PK and PD equivalence in patients with rheumatoid arthritis.
Number 2: FDA Commissioner, Dr Scott Gottlieb, has formed a new working group within the agency. The group will focus on increasing generic competition.
And Number 1: Pharmacist Kyle Skiermont, COO of Fairview Pharmacy Services, discusses his experience with payers and healthcare providers as they prepare for the impact of biosimilar drugs and non-medical switching.
Finally, last week, our newsletter asked you to share your thoughts on whether interchangeability will be important to the uptake of biosimilars. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read these articles and more, visit centerforbiosimilars.com.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.